Department of Neurology, Aarhus University Hospital
Aarhus, Central Jutland, 8200, Denmark
Location status: Recruiting
NCT Number: NCT06219759
The aim of this study is to describe the changes in the neuromuscular connection in patients with amyotrophic lateral sclerosis (ALS). The study consist of three substudies that have the following main hypothesis:
1. that ALS patients do not demonstrate equal capacity for muscle reinnervation and that reinnervation preserves muscle function and thereby slows down progression. 2. that blood concentrations of c-terminal agrin fragment (bCAF) reflect neuromuscular transmission deficiency and that blood concentration of neural cell adhesion molecule reflects degree of muscle denervation in patients. 3. that ALS patients with decrement when examined with repetitive nerve stimulation have more physical fatigue, slower progression, higher degree of reinnervation and higher bCAF compared to ALS patients without decrement.
There will be 3 inclusion groups.
1. patients referred for neurophysiological examination on suspicion of motor neuron disease. 2. healthy controls 3. disease control: patients with another motor neuron disease with slow progression.
All participants will be invited for at least 1 visit (baseline). If participants in group 1 eventually receive the diagnosis of ALS they will be invited for 2 additional visits 4 og 8 months after baseline visit, respectively.
Examinations will consist of:
* nerve conduction study * repetitive nerve stimulation (except for healthy controls) to examine impairment of the neuromuscular connection. * motor unit number estimation with MScanFit to estimate number and size of motor units. * ultrasound examination of muscles to measure size and condition of muscles. * questionnaires on fatigue and functional status. * blood sample for measurement of specialized analysis (c-terminal agrin fragment and neural cell adhesion molecule) and routine analysis (liver and kidney function as well as neurofilament light chain) * muscle strength assessment manually and by dynamometer to follow progression of muscle weakness * bioelectrical impedance measurement to follow the overall body composition.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Aarhus, Central Jutland, 8200, Denmark
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For disease controls the exclusion criteria are the same, but the inclusion criteria:
Observational study.
Time frame: From baseline and 8 months
Difference between fast and slow progressing patients in change in mean amplitude size of motor units as estimated by MScanFit motor unit number estimation.
Time frame: Baseline
Difference in blood concentration of c-terminal agrin fragment and neural cell adhesion molecule at baseline between ALS patients, healthy controls and ALS mimic disease patients.
Time frame: Baseline
Difference in proportion of participants with decrement between ALS patients and ALS mimic disease patients as well as degree of fatigue among ALS patients with and without neuromuscular transmission deficiency.
Time frame: Baseline, 4 months and 8 months.
Mean amplitude size measured by MScanFit technique.
Time frame: Baseline, 4 months and 8 months.
Motor unit number estimation measured by MScanFit technique.
Time frame: Baseline.
Mean amplitude size measured by MScanFit technique.
Time frame: Baseline, 4 months and 8 months.
Difference in measures from manual muscle strength testing.
Time frame: Baseline, 4 months and 8 months.
Measured on dynamometer.
Time frame: Baseline, 4 months and 8 months.
Measured with handgrip dynamometer.
Time frame: Baseline, 4 months and 8 months.
Decrement measured with repetitive nerve stimulation and mean amplitude size measured with MScanFit technique.
Time frame: Baseline, 4 months and 8 months.
Difference in blood measurements of c-terminal agrin fragment, neural cell adhesion molecule, neurofilament light chain and routine kidney and liver markers.
Time frame: Baseline, 4 months and 8 months.
Measured by ultrasound examination.
Time frame: Baseline, 4 months and 8 months.
Difference in scores from Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised. Scale 0-48, with 48 being the best.
Time frame: Baseline, 4 months and 8 months.
Difference in scores from Multidimensional Fatigue Inventory. Scale 4-20, with 20 indicating worst degree of fatigue.
Time frame: Baseline, 4 months and 8 months.
Difference in scores from Fatigue Severity Scale. Scale 9-63, with 63 indicating worst degree of fatigue.
Time frame: Baseline, 4 months and 8 months.
Measured by bioelectrical impedance analysis.
Contact information is provided by the study sponsor or research team.
University of Aarhus
Other
Reinnervation and Neuromuscular Transmission in Patients With Amyotrophic Lateral Sclerosis
Acronym: RANTAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06581861
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04363684
Amyotrophic Lateral Sclerosis, Basal Ganglia Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06578195
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06284161
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Clermont-Ferrand, France
View Trial Details